[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Ionis Pharmaceuticals (IONS) reports a proposed sale of 20,000 shares of common stock through Stifel Nicolaus & Company on 09/02/2025 on Nasdaq with an aggregate market value of $1,018,296. The filing states there are 159,391,229 shares outstanding.

The securities to be sold were acquired as restricted stock units on 01/15/2017 totaling 78,321 shares, with payment noted as cash. The filing also discloses a prior sale by Lynne Parshall of 5,000 shares on 08/06/2025 for gross proceeds of $209,646. The notice includes the standard representation that the seller has no undisclosed material information.

Positive

• Full disclosure of planned sale including broker, date, and aggregate value provides transparency
• Securities were acquired as RSUs in 2017, indicating these are long-held, vested awards rather than recent insider grants

Negative

• Insider sale of 20,000 shares could be viewed negatively by some investors despite being small relative to outstanding shares
• Filer contact and some issuer fields are blank in the provided content, limiting identification of the specific filer role

Insights

Securities Analyst

TL;DR: Routine insider sale of vested RSUs, limited near-term market impact given size versus outstanding shares.

The filing documents a proposed sale of 20,000 shares with an aggregate value just over $1.0 million, representing a de minimis portion of the issuer's 159.4 million shares outstanding. The shares were acquired as RSUs in 2017 and the seller previously completed a 5,000-share sale in August 2025, which shows execution of partial dispositions over time. This disclosure meets Rule 144 procedural requirements and offers transparency on timing and broker involvement.

Corporate Governance Expert

TL;DR: Disclosure is compliant and customary; repeated small disposals from long-held RSUs reduce questions about opportunistic selling.

The notice signals orderly dispositions through an established broker and documents long-standing equity grants (2017 RSUs). From a governance standpoint, the filing affirms the signer attests to no undisclosed material information and, absent larger concurrent filings or material news, this is a routine insider transaction rather than a corporate governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	20000	1018296.00	159391229	09/02/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2017	Restricted Stock Units	Issuer			78321	01/15/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Lynne Parshall 2855 Gazelle Ct Carlsbad CA 92010	Common Stock	08/06/2025	5000	209646.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Ionis (IONS) shares are proposed for sale under this Form 144?

The notice reports a proposed sale of 20,000 common shares scheduled for 09/02/2025.

What is the aggregate market value of the shares being sold in the Form 144?

The aggregate market value reported is $1,018,296.00.

When and how were the shares to be sold originally acquired?

The securities were acquired as restricted stock units on 01/15/2017, totaling 78,321 shares.

Has the person sold any Ionis shares recently?

Yes. The filing discloses a prior sale of 5,000 shares on 08/06/2025 for gross proceeds of $209,646.00 by Lynne Parshall.

Which broker is handling the proposed sale reported on this Form 144?

The sale is to be handled by Stifel Nicolaus & Company Inc with an address in St. Louis, MO.